Prosecution Insights
Prosecution Insights
9 pending office actions • 6 clients • 9 examiners • 8 art units • 0 of 9 (0%) have an AI response strategy ready • 4 patents granted in the last 365 days
Based on the USPTO statutory response window for each pending office action. 8 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 8 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 only | 1 (11%) |
| §101 + other | 1 (11%) |
| §103 only | 4 (44%) |
| Double-patenting + other | 3 (33%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| BLUMEL, BENJAMIN P | 1 | 70.7% | +30.6% |
| MYERS, CARLA J | 1 | 48.9% | +46.7% |
| SAOUD, CHRISTINE J | 1 | 58.0% | +37.7% |
| NICOL, ALEXANDER W | 1 | 42.9% | +43.1% |
| FETTEROLF, BRANDON J | 1 | 51.4% | +17.1% |
| BARRERA, IMMACULADA | 1 | 34.6% | +77.3% |
| SHUPE, ELIZABETH A | 1 | 65.7% | +46.8% |
| MITCHELL, EDWIN COLEMAN | 1 | 30.8% | +64.8% |
| AL-AWADI, DANAH J | 1 | 54.0% | +13.7% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18295893 | Synchronized Cell-Based Compositions | MYERS, CARLA J | 26d overdue |
| 18747563 | Antibodies to Andes Hantavirus, and Methods for Using Same | BLUMEL, BENJAMIN P | 7d |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17277342 | Octreotide Microsphere-Based Arterial Embolization for Treating Obesity | MITCHELL, EDWIN COLEMAN | 139d overdue |
| 18062642 | Lymphocyte-Based PKCe Test for Alzheimer's Disease | NICOL, ALEXANDER W | 105d overdue |
| 17499012 | ACE2-Targeted Compositions and Methods for Treating COVID-19 | SHUPE, ELIZABETH A | 79d overdue |
| 18295893 | Synchronized Cell-Based Compositions | MYERS, CARLA J | 26d overdue |
| 17999434 | Compositions and Methods for Treating Morphine, Heroin, and Alcohol Dependence | FETTEROLF, BRANDON J | 18d overdue |
| 18747563 | Antibodies to Andes Hantavirus, and Methods for Using Same | BLUMEL, BENJAMIN P | 7d |
| 17277400 | Flutamide Microsphere-Based Arterial Embolization for Treating Prostate Disorders | AL-AWADI, DANAH J | 39d |
| 18002066 | Anti-CCR5 Monoclonal Antibody-Based Compositions and Methods | SAOUD, CHRISTINE J | 75d |
| Client (Assignee) | Pending OAs |
|---|---|
| Maddon Advisors LLC | 3 |
| Biovena Science, LLC | 2 |
| UNIVERSIDAD DE CONCEPCION | 1 |
| NeuroGX LLC | 1 |
| NeuroDiagnostics LLC | 1 |
| Babak Behnam | 1 |
| Art Unit | Apps |
|---|---|
| 1671 | 2 |
| 1682 | 1 |
| 1645 | 1 |
| 1634 | 1 |
| 1626 | 1 |
| 1643 | 1 |
| 1619 | 1 |
| 1615 | 1 |
| App # | Title | Client | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|---|
| 18747563 | Antibodies to Andes Hantavirus, and Methods for Using Same | UNIVERSIDAD DE CONCEPCION | BLUMEL, BENJAMIN P | 1671 | §101 | Final Rejection | 7d | Pending | Jun 19, 2024 |
| 18295893 | Synchronized Cell-Based Compositions | Neurogx LLC | MYERS, CARLA J | 1682 | §101§102§103 | Non-Final OA | 26d overdue | Pending | Apr 05, 2023 |
| 18002066 | Anti-CCR5 Monoclonal Antibody-Based Compositions and Methods | Maddon Advisors LLC | SAOUD, CHRISTINE J | 1645 | §103DPOther | Non-Final OA | 75d | Pending | Dec 16, 2022 |
| 18062642 | Lymphocyte-Based PKCe Test for Alzheimer's Disease | Neurodiagnostics LLC | NICOL, ALEXANDER W | 1634 | §103 | Final Rejection | 105d overdue | Pending | Dec 07, 2022 |
| 17999434 | Compositions and Methods for Treating Morphine, Heroin, and Alcohol Dependence | Babak Behnam | FETTEROLF, BRANDON J | 1626 | §103 | Final Rejection | 18d overdue | Pending | Nov 21, 2022 |
| 17996019 | ACE2-Targeted Compositions and Methods for Treating COVID-19 | Maddon Advisors LLC | BARRERA, IMMACULADA | 1671 | §103DPOther | Final Rejection | — | Pending | Oct 12, 2022 |
| 17499012 | ACE2-Targeted Compositions and Methods for Treating COVID-19 | Maddon Advisors LLC | SHUPE, ELIZABETH A | 1643 | §103§112DP | Non-Final OA | 79d overdue | Pending | Oct 12, 2021 |
| 17277342 | Octreotide Microsphere-Based Arterial Embolization for Treating Obesity | Biovena Science, LLC | MITCHELL, EDWIN COLEMAN | 1619 | §103 | Final Rejection | 139d overdue | Pending | Mar 18, 2021 |
| 17277400 | Flutamide Microsphere-Based Arterial Embolization for Treating Prostate Disorders | Biovena Science, LLC | AL-AWADI, DANAH J | 1615 | §103 | Final Rejection | 39d | Pending | Mar 18, 2021 |
IP Author helps law firms respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial